Stocktoria

Anbio Biotechnology NNNN

Nasdaq · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2025-02-19 · LEI

Anbio Biotechnology statistics & valuation

Market cap$2.1B
P / E326.5×
P / B69.3×
Net margin74.1%
Return on equity21.2%
Return on capital19.1%
Graham number -84.7%$1.51

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($1.51); a green figure means the price is below it.

Profitability & efficiency

Net margin (%)
33.60% 29.00% 74.10% 202320242025
Gross margin (%)
50.10% 71.90% 87.20% 202320242025
Operating margin (%)
29.20% 24.40% 66.70% 202320242025
Return on equity (%)
15.20% 13.80% 21.20% 202320242025
Shares outstanding
21.4M 42.3M 43.7M 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
14.30% 12.50% 21.20% 202320242025
Free cash flow margin (%)
202320242025
Debt / equity (×)
202320242025
EPS ($)
$0.10 $0.06 $0.15 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Gross margin87.2%71.9%50.1%
Operating margin66.7%24.4%29.2%
Net margin74.1%29.0%33.6%
Return on assets21.2%12.5%14.3%
Return on equity21.2%13.8%15.2%
Current ratio344.3110.7115.86

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.